298 patents
Page 5 of 15
Utility
Combination Therapy Comprising A2A/A2B Inhibitors, PD-1/PD-L1 Inhibitors, and ANTI-CD73 Antibodies
28 Jul 22
Disclosed are combination therapies comprising administration of a CD73 inhibitor, an adenosine A2A or A2B receptor inhibitor, and a PD-1/PD-L1 inhibitor.
Hui Wang, Juan Carlos Almagro, Rebecca A. Buonpane, Peter Niels Carlsen, Taisheng Huang, Yong Li, Horacio G. Nastri, Chao Qi, Shaun M. Stewart, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Jing Zhou, Wenyu Zhu
Filed: 29 Dec 21
Utility
Combination Therapy Comprising Jak Pathway Inhibitor and Rock Inhibitor
21 Jul 22
The present application provides combination therapies comprising a JAK inhibitor and a ROCK inhibitor, and methods of using the same to treat disorders such as graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), and systemic sclerosis (scleroderma).
Michael Peel, Paul Smith
Filed: 10 Jan 22
Utility
Pyridine and Pyridimine Compounds As PI3K-GAMMA Inhibitors
21 Jul 22
Richard B. Sparks, Stacey Shepard, Andrew P. Combs, Andrew W. Buesking, Lixin Shao, Haisheng Wang, Nikoo Falahatpisheh
Filed: 25 Mar 22
Utility
Salts of Tam Inhibitors
21 Jul 22
The present application provides salt forms of N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as processes and intermediates related thereto.
Zhongjiang Jia, Yongzhong Wu, Yongchun Pan, Jiacheng Zhou, Qun Li
Filed: 13 Aug 21
Utility
Pyrazolopyridine Compounds and Uses Thereof
21 Jul 22
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Hai Fen Ye, Qinda Ye, Wenqing Yao
Filed: 22 Dec 21
Utility
Jak Inhibitor with a Vitamin D Analog for Treatment of Skin Diseases
30 Jun 22
The present disclosure relates to topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization, using (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.
Paul SMITH, Zheng ZHANG, Melissa PARKER
Filed: 3 Dec 21
Utility
Oral Formulation for a PD-L1 Inhibitor
23 Jun 22
Disclosed are oral formulations for a compound which modulates PD-1/PD-L1 protein/protein interaction, or a pharmaceutically acceptable salt thereof, which do not require cold chain storage.
Yonglai Yang, Trupti Sheth, Xinsheng Xie
Filed: 17 Dec 21
Utility
Heterocyclic Compounds As Immunomodulators
23 Jun 22
Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
Filed: 15 Feb 22
Utility
ANTI-CD19 Combination Therapy
16 Jun 22
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and R-CHOP or an anti-CD19 antibody, lenalidomide, and R-CHOP for use in the treatment of diffuse large B cell lymphoma.
Günter FINGERLE-ROWSON, Wolfram BRUGGER, Oliver MANZKE, Francis SEGUY
Filed: 3 Dec 21
Utility
Bicyclic Heteroarylaminoalkyl Phenyl Derivatives As PI3K Inhibitors
9 Jun 22
Yun-Long Li, Andrew P. Combs
Filed: 24 Aug 21
Utility
JAK1 Pathway Inhibitors for the Treatment of Vitiligo
9 Jun 22
This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.
Paul Smith, Kurt Andrew Brown, Michael D. Howell, Fiona Kuo, James Lee, Leandro Luiz Dos Santos, Beth Rumberger
Filed: 8 Dec 21
Utility
Tricyclic Urea Compounds As JAK2 V617F Inhibitors
2 Jun 22
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
Filed: 1 Jul 21
Utility
Solid Forms of an HPK1 Inhibitor
26 May 22
The present invention relates to salt forms of the hematopoietic progenitor kinase 1 (HPK1) inhibitors N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide and N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide, including methods of preparation thereof, where the compounds are useful in the treatment of HPK1 mediated diseases such as cancer.
Zhongjiang Jia, William Frietze
Filed: 25 Jun 21
Utility
Process of Preparing a PD-1/PD-L1 Inhibitor
12 May 22
The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
Filed: 5 Nov 21
Utility
Process for Making a PD-1/PD-L1 Inhibitor and Salts and Crystalline Forms Thereof
12 May 22
This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.
Dengjin Wang, Daniel Carper, Zhongjiang Jia, Bo Shen, Joseph A. Sclafani, Robert Wilson, Jiacheng Zhou, Osama Suleiman, Mark Wright
Filed: 5 Nov 21
Utility
Crystalline Form of a PD-1/PD-L1 Inhibitor
12 May 22
The present invention relates to crystalline forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, and related synthetic intermediates, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
Zhongjiang Jia, Shili Chen, Mei Li, Pingli Liu, Yongchun Pan, Yongzhong Wu, Jiacheng Zhou
Filed: 5 Nov 21
Utility
Fused Pyrazine Derivatives As A2A / A2B Inhibitors
5 May 22
Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
Filed: 13 Oct 21
Utility
Use of Pyrazolopyrimidine Derivatives for the Treatment of PI3K-DELTA Related Disorders
21 Apr 22
Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Song Mei, Brent Douty
Filed: 30 Jun 21
Utility
Crystalline Forms of a Phosphoinositide 3-KINASE (PI3K) Inhibitor
14 Apr 22
The present invention relates to salts and crystalline forms of 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, and crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, which are PI3K inhibitors useful in the treatment of cancer and other diseases.
Brent Douty, David M. Burns, Andrew P. Combs, Zhongjiang Jia, Daniel Levy, Eddy W. Yue
Filed: 27 Oct 21
Utility
Heterocyclic Compounds As Immunomodulators
24 Mar 22
Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao
Filed: 4 May 21